专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009128810A1 APPARATUS AND METHOD FOR NEUROCRANIAL ELECTROSTIMULATION 审中-公开
标题翻译：神经电生理装置及方法
公开(公告)号：WO2009128810A1
公开(公告)日：2009-10-22
申请号：PCT/US2008/010849
申请日：2008-09-18
申请人： RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK , BIKSON, Marom , DATTA, Abhishek , BATTAGLIA, Fortunato , ELWASSIF, Maged
发明人： BIKSON, Marom , DATTA, Abhishek , BATTAGLIA, Fortunato , ELWASSIF, Maged
IPC分类号： A61N1/00
CPC分类号： A61N1/0529 , A61N1/36021 , A61N1/36025
摘要： There is provided method and apparatus for enhancing focality of neurocranial electrostimulation, including: providing a first plurality of electrodes having at least one electrode; providing a second plurality of electrodes having at least two electrodes; locating the first and the second plurality of electrodes on cranium of a subject and supplying electric current of opposite polarities to the first and the second plurality of electrodes. At least one electrode of the first plurality of electrodes is surrounded by at least two electrodes of the second plurality of electrodes. The enhanced focal stimulation may be used to treat ailments or augment cognitive performance. There are also provided methods for treating brain related ailments and performance augmentation.
摘要翻译：提供了用于增强神经颅肌电刺激的聚焦的方法和装置，包括：提供具有至少一个电极的第一多个电极; 提供具有至少两个电极的第二多个电极; 将第一和第二多个电极定位在受试者的颅骨上，并向第一和第二多个电极提供相反极性的电流。第一多个电极中的至少一个电极被第二多个电极的至少两个电极包围。增强的局部刺激可以用于治疗疾病或增加认知表现。还提供了治疗脑相关疾病和增加性能的方法。

2. 发明申请

WO2003093442A2 CELL CULTURES FROM ANIMAL MODELS OF ALZHEIMER'S DISEASE FOR SCREENING AND TESTING DRUG EFFICACY 审中-公开
标题翻译：来自阿尔茨海默病的动物模型的细胞培养用于筛选和测试药物效力
公开(公告)号：WO2003093442A2
公开(公告)日：2003-11-13
申请号：PCT/US2003/013948
申请日：2003-05-05
申请人： NEW YORK STATE DEPARTMENT OF MENTAL HYGIENE OFFICE OF MENTAL HEALTH , ARANCIO, Ottavio , MATHEWS, Paul, M. , SCHMIDT, Stephen, D. , NIXON, Ralph, A. , BATTAGLIA, Fortunato , TRINCHESE, Fabrizio , LIU, Shumin
发明人： ARANCIO, Ottavio , MATHEWS, Paul, M. , SCHMIDT, Stephen, D. , NIXON, Ralph, A. , BATTAGLIA, Fortunato , TRINCHESE, Fabrizio , LIU, Shumin
IPC分类号： C12N
CPC分类号： G01N33/502 , A01K2217/05 , A01K2227/105 , A01K2267/0312 , G01N33/5008 , G01N33/5014 , G01N33/5058 , G01N33/6896
摘要： The present invention describes a dissociated cell culture system comprising cells of the hippocampus, one of the brain areas affected by Alzheimer’s Disease (AD) or amyloid beta-related diseases. This culture system comprises hippocampal neuronal and glial cells from animal models of AD, particularly, but not limited to, double transgenic mice expressing both the human APP mutation (K670N:M671L) (mAPP), and the human PS1 mutation (M146L)(mPS1), and serves as a powerful tool for the screening and testing of compounds and substances, e.g., drugs, for their ability to affect, treat, or prevent AD or β-amyloid-related diseases. The effects of a test substance on the cells in this culture system can be quantitatively assessed to determine if the test substance affects the cells biochemically and/or electrophysiologically, and/or optically, and/or immunocytochemically. The present in vitro culture system is advantageous for AD drug screening, because it is rapid and efficient. By contrast, even in the fastest animal model of AD, pathology does not start before the end of the second month. If such in vivo animal models are used, it is necessary to wait at least the two month time duration or longer to test for drug efficacy for AD treatment or prevention. At the same time the present invention provides a tool for production of amyloid-beta that can be used for electrophysiological, behavioral, and toxicological studies.
摘要翻译：本发明描述了解离的细胞培养系统，其包括海马细胞，受阿尔茨海默病（AD）或淀粉样蛋白β相关疾病影响的脑区之一。该培养系统包括来自AD动物模型的海马神经元和神经胶质细胞，特别但不限于，表达人APP突变（K670N：M671L）（mAPP）和人类PS1突变（M146L）（mPS1）的双转基因小鼠），并且用作筛选和测试化合物和物质（例如药物）对其影响，治疗或预防AD或β-淀粉样蛋白相关疾病的能力的有力工具。可以定量评估测试物质对该培养系统中细胞的影响，以确定测试物质是否通过生物化学和/或电生理学，和/或光学和/或免疫细胞化学方法影响细胞。目前的体外培养体系对于AD药物筛选是有利的，因为它是快速和有效的。相比之下，即使在AD的最快动物模型中，病理学也不会在第二个月之前开始。如果使用这样的体内动物模型，则需要等待至少两个月的持续时间或更长时间来测试AD治疗或预防的药物功效。同时，本发明提供了可用于电生理，行为和毒理学研究的淀粉样蛋白-β生产工具。

3. 发明申请

WO2003093442A3 CELL CULTURES FROM ANIMAL MODELS OF ALZHEIMER'S DISEASE FOR SCREENING AND TESTING DRUG EFFICACY 审中-公开
公开(公告)号：WO2003093442A3
公开(公告)日：2003-11-13
申请号：PCT/US2003/013948
申请日：2003-05-05
申请人： NEW YORK STATE DEPARTMENT OF MENTAL HYGIENE OFFICE OF MENTAL HEALTH , ARANCIO, Ottavio , MATHEWS, Paul, M. , SCHMIDT, Stephen, D. , NIXON, Ralph, A. , BATTAGLIA, Fortunato , TRINCHESE, Fabrizio , LIU, Shumin
发明人： ARANCIO, Ottavio , MATHEWS, Paul, M. , SCHMIDT, Stephen, D. , NIXON, Ralph, A. , BATTAGLIA, Fortunato , TRINCHESE, Fabrizio , LIU, Shumin
IPC分类号： A01K67/00
摘要： The present invention describes a dissociated cell culture system comprising cells of the hippocampus, one of the brain areas affected by Alzheimer’s Disease (AD) or amyloid beta-related diseases. This culture system comprises hippocampal neuronal and glial cells from animal models of AD, particularly, but not limited to, double transgenic mice expressing both the human APP mutation (K670N:M671L) (mAPP), and the human PS1 mutation (M146L)(mPS1), and serves as a powerful tool for the screening and testing of compounds and substances, e.g., drugs, for their ability to affect, treat, or prevent AD or β-amyloid-related diseases. The effects of a test substance on the cells in this culture system can be quantitatively assessed to determine if the test substance affects the cells biochemically and/or electrophysiologically, and/or optically, and/or immunocytochemically. The present in vitro culture system is advantageous for AD drug screening, because it is rapid and efficient. By contrast, even in the fastest animal model of AD, pathology does not start before the end of the second month. If such in vivo animal models are used, it is necessary to wait at least the two month time duration or longer to test for drug efficacy for AD treatment or prevention. At the same time the present invention provides a tool for production of amyloid-beta that can be used for electrophysiological, behavioral, and toxicological studies.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式